Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.

作者:D. Ross, Camidge; Solange, Peters; Tony, Mok; Shirish M., Gadgeel; Parneet K., Cheema; Nick, Pavlakis; Filippo, De Marinis; Daniil L., Stroyakovskiy; Byoung Chul, Cho; Li, Zhang; Denis, Moro-Sibilot; Ali Hassan, Zeaiter; Emmanuel, Mitry; Bogdana, Balas; Barbara, Müller; Alice, Shaw
来源:Journal of Clinical Oncology, 2018, 36(15_suppl): 9043-9043.
DOI:10.1200/jco.2018.36.15_suppl.9043
  • 出版日期2018-5-20
  • 单位中山大学; Massachusetts General Hospital; University of Michigan Ann Arbor; university of Colorado; University of Michigan, Ann Arbor; The University of Colorado; University of Michigan-Ann Arbor; University of Michigan,Ann Arbor